Search
Isoniazid
go.drugbank.com/drugs/DB00951ApprovedInvestigationalAntibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePromestriene
go.drugbank.com/drugs/DB12487InvestigationalIn addition, promestriene was in phase IV of the clinical trial to study its treatment of patients with vaginosis, bacterial, but that studied was terminated. … Promestriene’s potential for treating vaginal atrophy symptoms associated with aromatase inhibitor treatment would be precluded if its minimal absorption leads to estrogen-like effects on cell proliferation
Categories: EstranesRobenidine
go.drugbank.com/drugs/DB11542ExperimentalVet approvedFarmers alternate the use of robenidine with other antimicrobial agents in order to maintain effectiveness by slowing the development of antimicrobial resistance. … Despite the availability of other agents to treat coccidiosis, robenidine has been proven to be effective in delaying the development of antibiotic resistance through intermittent and rotating use with
CT-011
go.drugbank.com/drugs/DB05916InvestigationalCT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating a...
Artesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigational[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]
Zafirlukast
go.drugbank.com/drugs/DB00549ApprovedZafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages
Categories: Agents to Treat Airway DiseaseSynonyms: 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide, cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamateBrodalumab
go.drugbank.com/drugs/DB11776ApprovedInvestigationalBrodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.